Mechanism of Action
Simvastatin is a semi-synthetic lipid-lowering agent. Structurally, it contains a hydronaphthalene ring and acts as a prodrug in the form of an inactive lactone. Once inside the body, the substance undergoes hydrolysis to become an active $eta$-hydroxy acid.
The primary biochemical mechanism involves the inhibition of HMG-CoA reductase (3-hydroxy-3-methylglutaryl-coenzyme A reductase). The drug blocks endogenous cholesterol synthesis in hepatocytes at an early stage—during the formation of mevalonic acid (mevalonate).
For the drug to enter liver cells during first-pass metabolism, the OATP1B1 membrane transporter is critically important. It ensures efficient uptake of statins from the blood, which simultaneously guarantees delivery to the therapeutic target while lowering systemic concentration and preventing toxic effects (particularly myopathies).
Pharmacological Effects
The blockade of cholesterol synthesis triggers a compensatory hepatic response. In response to decreased intracellular cholesterol, hepatocytes undergo up-regulation, increasing the density and number of LDL receptors on their membranes.
Due to the increased number of receptors, receptor-mediated endocytosis is enhanced. Low-density lipoproteins (the atherogenic fraction) are actively cleared from blood plasma and taken up into cells. The net effect is a significant reduction in plasma LDL concentration.
Indications and Place in Therapy
The drug is prescribed to correct the lipid profile and prevent cardiovascular complications. Simvastatin is part of standard combination therapy for ischemic heart disease (IHD) to prevent myocardial infarction.
In complication prevention regimens, it is combined with antiplatelet agents (acetylsalicylic acid, clopidogrel) and other lipid-lowering medications.
Administration and Dosing
The drug is available as tablets containing 10, 20, 40, and 80 mg.
Administration and Dosage: Orally, 10 mg once daily. If necessary and efficacy is insufficient, the daily dose may be gradually increased by a physician up to 40 mg.
Class Characteristics and Safety
As a prodrug, simvastatin requires metabolic activation in the liver. The presence of transport proteins such as OATP1B1 reduces the systemic concentration of the substance and minimizes the risk of adverse effects (e.g., skeletal muscle injury).
In classifications of statins by source, simvastatin, along with pravastatin, is classified as a semi-synthetic agent, representing a chemical derivative of natural fungal lovastatin.